). WES was conducted at a mean depth of 277×. In total, 7269 mutations were identified, and 7026 (97%) somatic mutations were validated by a separate bespoke capture sequencing experiment at mean depth of 863× (table S2). The numbers of mutations varied substantially between tumors (fig. S1), but no significant correlations were identified between mutation burden and age, gender, tumor size, lymph node status, or smoking status.
A useful approach when considering ITH is to depict a given tumor as a tree structure with the trunk representing ubiquitous mutations present in all regions of the tumor, branches representing heterogeneous mutations present in only some regions of the tumor, and private branches representing mutations that are present only in one region of the tumor-analogous to a phylogenetic tree. Placement of mutations on trunks versus branches reflects relative molecular time of acquisition, with branch mutations occurring, by definition, subsequent to trunk mutations. We applied this approach to multiregion sequencing data from these 11 lung adenocarcinomas. Evidence for ITH was found in each tumor studied. On average, 76% of all mutations were detected in all regions of the same tumors. However, the phylogenetic structure varied considerably between tumors ( Fig. 1) . We then characterized known cancer gene mutations, defined as nonsynonymous mutations identical to those previously reported in known cancer genes (18) (19) (20) (21) (22) (23) or truncating mutations in known tumor suppressor genes, in the context of the derived phylogenetic tree structures. Thirteen of 14 known cancer gene point mutations were mapped to the trunks of the phylogenetic trees ( Fig. 1 and table S3 ), which indicated that these mutations were acquired relatively early during evolution of these 11 tumors. In contrast to ccRCC, these data suggest that single-region sampling may be sufficient to identify the majority of known cancer gene mutations in localized lung adenocarcinomas.
We were also able to evaluate copy number changes relative to ITH. In contrast to ccRCC (16, 17, 24) , we did not observe substantial differences in large-scale chromosome aberrations ( fig. S2A) , and the log2 ratio profiles were similar between different regions within the same tumors ( fig. S2B and table S4 ). Furthermore, amplification or deletion of known cancer genes (22) , as well as their relative placement on the phylogenetic trees, were delineated for these 11 lung adenocarcinomas. All of these events were mapped to the trunks of the phylogenetic trees (Fig. 1) , which suggested that, like known cancer gene point mutations discussed above, amplification and/or deletion of known cancer genes were also early molecular events for these 11 tumors. Previous work in breast cancer also suggested that known cancer gene mutations were relatively early genetic events shared by all subclones of individual breast cancers (13 With a median follow-up of 21 months after surgery at the time of this report, three patients have had disease relapse. These three patients had a significantly larger proportion of subclonal nontrunk mutations (branch plus private branch mutations) in their primary tumors than patients without relapse (average 40% in relapsed patients versus 17% in patients without relapse, P = 0.006 by t test) (Fig. 1) . Although the sample size is small, these findings suggest the possibility that subclonal mutations may be important for cancer progression and that larger subclonal mutation fraction may be associated with an increased likelihood of postsurgical relapse in this subset of lung adenocarcinoma patients.
Analysis of NGS data relies heavily on adequate sequencing depth to make high-accuracy consensus base calls. We compared our WES data (average sequencing depth 277×) with deep sequencing data (average sequencing depth 863×) to assess the effect of sequencing depth on detecting known cancer gene mutations. In tumor 499, a canonical KRAS p.G12C mutation was detected in only one of four tumor regions at exome depth but was detected in all four tumor regions at increased sequencing depth (table S2) . Extending this analysis, we then compared deep sequencing data with WES data in defining ITH. The result showed many branch and private branch mutations defined by WES were detectable in all regions of individual tumors with increasing sequencing depth (Fig. 2) . Taken together, these results indicate that considerable depth of sequencing will be necessary to detect cancer gene mutations and to accurately characterize ITH of lung adenocarcinomas.
Next, we analyzed the mutational spectrum of these 11 lung adenocarcinomas. Consistent with previous studies (18) (19) (20) 25) , different mutation spectra were observed in smokers and nonsmokers. Three never-smokers (cases 292, 339, and 356) showed C>T-predominant mutation profiles. Three former smokers who had quit more than 20 years before (cases 270, 472, and 4990) and one former smoker who had a 25 pack-year (pack-year = number of packs per day × number of years) history of smoking and quit 6 years ago (case 283) also showed C>T-predominant mutation profiles, as in nonsmokers. Two former smokers who had a >50 pack-year history of smoking and had quit 5 years before (cases 317 and 499) and one former smoker, who had a 25 pack-year history of smoking and had quit only 2.5 years before (case 330) showed C>A-predominant mutation profiles consistent with the mutation profile of cigarette smoke exposure. The only current smoker, who had a 20 pack-year history of smoking but had cut down to two cigarettes a day at the time of cancer diagnosis (case 324), showed an equivalent portion of C>T (26%) versus C>A (21%) substitutions in her tumor (Fig. 3A) . These results indicate that tumor mutation spectra in former smokers reflect not only quantity of smoking exposure but also time since smoking cessation.
We next compared the mutational spectrum of trunk versus nontrunk mutations to explore the relative contribution of mutational processes over time. Significant differences in mutational spectrum were observed in six tumors, which indicated that specific mutational processes were likely operative at different times during development of these tumors (Fig. 3, B and C) . Of interest, two former smokers (cases 317 and 330) and the current smoker (case 324) showed significant differences between trunk and nontrunk mutation spectrum with a shift from smokingassociated C>A transversions in trunk mutations to nonsmoker-associated C>T transitions in nontrunk mutations.
Recent evidence has suggested that APOBEC activity is a major source for C>T and C>G mutations 258 10 OCTOBER 2014 • VOL 346 ISSUE 6206 sciencemag.org SCIENCE Fig. 2 . Distribution of trunk, branch, and private branch mutations defined by exome sequencing (average sequencing depth of 277×) versus deep sequencing (average sequencing depth of 863×). Only validated mutations meeting the following criteria are included: total counts in tumor DNA ≥ 100; total counts in germline DNA ≥ 50; variant allele frequency (VAF) of ≥5% in tumor DNA, and VAF = 0 in germline DNA. 12, 26) . We therefore investigated whether there is evidence of an APOBEC mutational process in this subset of lung adenocarcinomas. On average, 28% of all mutations had a specific substitution pattern (C>T/G at TpCpW sites, where W is A or T), consistent with an APOBEC-mediated process ( fig. S3 ). APOBEC mutation signature enrichment was found to be more pronounced for nontrunk mutations compared with trunk mutations in 7 of the 11 patients; however this difference was statistically significant only for case 330 (Fig. 3D) . These data suggest that an APOBEClike process is contributing substantially to the mutations found in this subset of lung adenocarcinomas and that the process tends to be more pronounced in later, subclonal mutations; this further highlights the dynamic nature of mutational processes in play.
Substantial variation in the allele frequency of somatic mutations within each individual tumor region from a given tumor was observed in this set of lung adenocarcinomas ( fig. S4A ). To more formally characterize subclonal fraction within each tumor region, we used the ABSOLUTE algorithm (27) . These analyses demonstrated that at least 29 out of 48 individual tumor regions showed evidence of intraregional subclonal populations. The distribution of clonal and subclonal mutations was different among the sampled regions within the same tumors in some patients ( fig.  S4B ), which suggests that single-biopsy analysis would be inadequate to fully represent ITH in these tumors.
To explore the possible implications of these data on translation to routine ITH assessment for in clinical practice, we repeated the ABSO-LUTE analysis on the combined sequencing data from all tumor regions of each patient to assess the global ITH on a per-patient level, defined by the relative proportion of subclonal mutations. Similar to the phylogenetic analyses, all three patients with relapsed disease had larger subclonal fractions in their primary tumors (average 41% in patients with relapse versus 24% in patients without relapse, P = 0.045 by t test) ( fig.  S5A ). Use of a complementary Bayesian Dirichlet process (13) on the per-patient combined data revealed the same trend (average subclonal mutations 66% in patients with relapse versus 36% in patients without relapse, P = 0.035 by t test) (fig. S5B) . These results suggest that a measure of overall subclonal fraction may be of interest from a prognostic standpoint in this population of patients.
Resectable localized disease accounts for 30 to 50% of all non-small cell lung cancers, with increasing prevalence as screening is more widely implemented (28) (29) (30) . Given that this subset of patients has tumors surgically resected as standard of care, there is an opportunity to confirm these preliminary observations by deep sequencing multiregion samples obtained from resected tumors. The questions of whether sequencingtargeted cancer gene panels versus WES will yield sufficient mutation data for meaningful analyses and the most appropriate algorithms for analyses will need to be addressed in order to fully test if the clinical correlation suggested in these data are borne out in larger patient cohorts.
Evidence of marked regional ITH in ccRCC suggested substantial challenges to personalized oncology based on single-tumor biopsy to portray the mutational landscape. This study, however, provides evidence that ITH patterns may be different between cancer types. With the caveat of limited sample size fully acknowledged, these data suggest that, although multiregion sampling is needed to fully assess ITH complexity, singlebiopsy analysis at appropriate depth might be sufficient to identify the majority of known cancer gene mutations in this subset of lung adenocarcinomas. Studies in much larger cohorts, ideally with comprehensive clinical annotation and repeat biopsy at relapse, are needed to fully understand the clinical impact of ITH and insights afforded by these types of analyses. Furthermore, extension of research to epigenetic and phenotypic assessment through regional DNA methylation, chromatin state, and RNA and/or protein expression studies over time and under treatment is needed to fully understand the impact of ITH on the biology of the cancer itself and its impact on the clinical phenotype of cancer patients.
